Redx further strengthens Management Team and Board with appointment of Dr James Mead as CFO

19 Nov 2018

Alderley Park, 19 November 2018 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce the appointment of Dr James Mead as new full time Chief Financial Officer (CFO) and an Executive Director of the Board, effective 1 February 2019. He takes over from Dominic Jackson who has served as interim Chief Financial Officer and Executive Director of the Board since 3 November 2017 and who will step down at the end of January 2019.

James, aged 41, is an experienced finance professional in the sector, having held a variety of senior roles over a 16-year career at AstraZeneca, including Chief Financial Officer of AstraZeneca Netherlands, Finance Director for multiple clinical development project teams and Director of Investor Relations. James holds a PhD in Molecular Biology and a first-class honours degree in Biochemistry from Cardiff University. He is also an Associate Member of the Chartered Institute of Management Accountants.

Lisa Anson, Chief Executive Officer of Redx plc, said: “I am delighted to have James join our team at Redx. He will bring a dynamic and professional approach and will play an integral role as we focus on progressing delivery of our strategy. Personally, and on behalf of the Board, I would like to thank Dominic for his role in resolving many legacy issues and stabilising the company over recent months.  He has been instrumental in delivering a reduction in operating costs of one-third, and significantly improving forecasting and cash discipline.  We wish him continued success within private equity.

Dr James Mead, Chief Financial Officer Designate of Redx Pharma plc, commented: “I am incredibly excited to be joining Lisa and the team on the next stage of Redx’s journey towards building a leading Biotech company.  Redx now has a clear, focused strategy coupled with a pipeline of exciting assets targeting areas of significant unmet medical need.  I look forward to working with the team and the Board to develop Redx to its full potential and, in doing so, drive value creation for our shareholders.”

The following information is being disclosed pursuant to Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Full name: James Robert Mead

Dr. Mead does not hold any shares in the Company.

Dr. Mead is a former director of the following companies: AstraZeneca B.V., AstraZeneca Holdings B.V., AstraZeneca Continent B.V., AstraZeneca Sigma B.V., AstraZeneca Jota B.V., AstraZeneca Gamma B.V., AstraZeneca Zeta B.V., AstraZeneca Rho B.V., AstraZeneca Finance B.V., AstraZeneca Finance Coöperatief W.A. and AstraZeneca India Private Ltd.

For further information, please contact:

 

Redx Pharma Plc T: +44 1625 469 920
Iain Ross, Chairman

Lisa Anson, Chief Executive Officer

 
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)  T: +44 20 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705 9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727 1000
Simon Conway/Stephanie Cuthbert

 

About Redx Pharma Plc 

 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/